Dr Margaret Duffy, CSO and Dr Matilde Saggese, CMO will be attending and will showcase the OCTOPOD-IV Phase I/IIa clinical trial of THEO-260, a novel oncolytic immunotherapy, given by intravenous delivery in patients with ovarian cancer. OCTOPOD-IV (NCT06618235) is a first-in-human, multi-centre trial to assess safety, tolerability and preliminary efficacy of THEO-260 in patients with high-grade serous ovarian or endometrioid cancer. Matilde Saggese, MD,MD (Res), Theolytics’CMO,said,“Recruitment is now well under way for our first ever clinical trial with THEO-260. THEO-260 is being evaluated in a Phase I/IIa clinical trial by intravenous delivery in ovarian cancer patients (OCTOPOD-IV) (NCT06618235). A clinical study of THEO-260 administered by intraperitoneal delivery to advanced ovarian cancer patients (OCTOPOD-IP) is also underway in the US in collaboration with The University of Texas MD Anderson Cancer Center (NCT07211659).